175 related articles for article (PubMed ID: 16937307)
1. Serial changes of international prostate symptom score following I-125 prostate brachytherapy.
Ohashi T; Yorozu A; Toya K; Saito S; Momma T
Int J Clin Oncol; 2006 Aug; 11(4):320-5. PubMed ID: 16937307
[TBL] [Abstract][Full Text] [Related]
2. Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity after permanent interstitial brachytherapy.
Hinerman-Mulroy A; Merrick GS; Butler WM; Wallner KE; Allen Z; Adamovich E
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1367-82. PubMed ID: 15275722
[TBL] [Abstract][Full Text] [Related]
3. Preimplant predictive factors of urinary retention after iodine 125 prostate brachytherapy.
Mabjeesh NJ; Chen J; Stenger A; Matzkin H
Urology; 2007 Sep; 70(3):548-53. PubMed ID: 17905113
[TBL] [Abstract][Full Text] [Related]
4. Urinary symptom flare following I-125 prostate brachytherapy.
Cesaretti JA; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):1085-92. PubMed ID: 12829146
[TBL] [Abstract][Full Text] [Related]
5. The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy.
Niehaus A; Merrick GS; Butler WM; Wallner KE; Allen ZA; Galbreath RW; Adamovich E
Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):136-43. PubMed ID: 16198062
[TBL] [Abstract][Full Text] [Related]
6. Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity.
Allen ZA; Merrick GS; Butler WM; Wallner KE; Kurko B; Anderson RL; Murray BC; Galbreath RW
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):981-7. PubMed ID: 15989998
[TBL] [Abstract][Full Text] [Related]
7. Preimplant factors affecting prostate D90 after transperineal interstitial prostate brachytherapy with loose (125)I seeds.
Sugawara A; Nakashima J; Kunieda E; Nagata H; Mizuno R; Takeda A; Seki S; Shiraishi Y; Kouta R; Oya M; Shigematsu N
Keio J Med; 2012; 61(3):89-94. PubMed ID: 23018491
[TBL] [Abstract][Full Text] [Related]
8. The impact of prostate volume and neoadjuvant androgen-deprivation therapy on urinary function following prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Allen ZA; Lief JH; Hinerman-Mulroy A; Galbreath RW
Cancer J; 2004; 10(3):181-9. PubMed ID: 15285928
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Lief JH; Galbreath RW
Urology; 2002 Oct; 60(4):650-5. PubMed ID: 12385927
[TBL] [Abstract][Full Text] [Related]
10. Urethral dose and increment of international prostate symptom score (IPSS) in transperineal permanent interstitial implant (TPI) of prostate cancer.
Murakami N; Itami J; Okuma K; Marino H; Nakagawa K; Ban T; Nakazato M; Kanai K; Naoi K; Fuse M
Strahlenther Onkol; 2008 Oct; 184(10):515-9. PubMed ID: 19016040
[TBL] [Abstract][Full Text] [Related]
11. Factors predicting for urinary morbidity following 125iodine transperineal prostate brachytherapy.
Williams SG; Millar JL; Duchesne GM; Dally MJ; Royce PL; Snow RM
Radiother Oncol; 2004 Oct; 73(1):33-8. PubMed ID: 15465143
[TBL] [Abstract][Full Text] [Related]
12. Predictive factors for urinary toxicity after iodine-125 prostate brachytherapy with or without supplemental external beam radiotherapy.
Eriguchi T; Yorozu A; Kuroiwa N; Yagi Y; Nishiyama T; Saito S; Toya K; Hanada T; Shiraishi Y; Ohashi T; Shigematsu N
Brachytherapy; 2016; 15(3):288-295. PubMed ID: 26924022
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up of International Prostate Symptom Score (IPSS) in men following prostate brachytherapy.
Li X; Fang D; Cooperberg MR; Whitson JM; Lue TF; Zhou L; Shinohara K
World J Urol; 2014 Aug; 32(4):1061-6. PubMed ID: 24141807
[TBL] [Abstract][Full Text] [Related]
14. Temporal resolution of urinary morbidity following prostate brachytherapy.
Merrick GS; Butler WM; Lief JH; Dorsey AT
Int J Radiat Oncol Biol Phys; 2000 Apr; 47(1):121-8. PubMed ID: 10758313
[TBL] [Abstract][Full Text] [Related]
15. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.
Vargas C; MartÃnez A; Galalae R; Demanes J; Harsolia A; Schour L; Nuernberg N; Gonzalez J
Prostate Cancer Prostatic Dis; 2006; 9(3):245-53. PubMed ID: 16786040
[TBL] [Abstract][Full Text] [Related]
16. The nature and extent of urinary morbidity in relation to prostate brachytherapy urethral dosimetry.
Neill M; Studer G; Le L; McLean M; Yeung I; Pond G; Crook JM
Brachytherapy; 2007; 6(3):173-9. PubMed ID: 17681239
[TBL] [Abstract][Full Text] [Related]
17. Late urinary side effects 10 years after low-dose-rate prostate brachytherapy: population-based results from a multiphysician practice treating with a standardized protocol and uniform dosimetric goals.
Keyes M; Miller S; Pickles T; Halperin R; Kwan W; Lapointe V; McKenzie M; Spadinger I; Pai H; Chan EK; Morris WJ
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):570-8. PubMed ID: 25151536
[TBL] [Abstract][Full Text] [Related]
18. [Clinical outcome of intermediate risk prostate cancer treated with iodine 125 monotherapy: The Hotel-Dieu of Quebec experience].
Zebentout O; Apardian R; Beaulieu L; Harel F; Martin AG; Vigneault E
Cancer Radiother; 2010 Jun; 14(3):183-8. PubMed ID: 20418145
[TBL] [Abstract][Full Text] [Related]
19. Dysuria after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Murray B; Zeroski D; Lief JH
Int J Radiat Oncol Biol Phys; 2003 Mar; 55(4):979-85. PubMed ID: 12605976
[TBL] [Abstract][Full Text] [Related]
20. Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients.
Keyes M; Miller S; Moravan V; Pickles T; McKenzie M; Pai H; Liu M; Kwan W; Agranovich A; Spadinger I; Lapointe V; Halperin R; Morris WJ
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1023-32. PubMed ID: 19111402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
